Novartis will buy cholesterol drug developer The Medicines Company for $9.7 billion, the latest and largest in a string of deals under CEO Vas Narasimhan aimed at reshaping the Swiss pharmaceutical company around newer technologies and higher-margin prescription therapies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,